167 related articles for article (PubMed ID: 38081808)
1. Mint3-depletion-induced energy stress sensitizes triple-negative breast cancer to chemotherapy via HSF1 inactivation.
Tanaka N; Okada H; Yamaguchi K; Seki M; Matsubara D; Gotoh N; Suzuki Y; Furukawa Y; Yamashita T; Inoue JI; Kaneko S; Sakamoto T
Cell Death Dis; 2023 Dec; 14(12):815. PubMed ID: 38081808
[TBL] [Abstract][Full Text] [Related]
2. ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells.
Koh M; Lim H; Jin H; Kim M; Hong Y; Hwang YK; Woo Y; Kim ES; Kim SY; Kim KM; Lim HK; Jung J; Kang S; Park B; Lee HB; Han W; Lee MS; Moon A
Autophagy; 2024 Mar; 20(3):659-674. PubMed ID: 38290972
[TBL] [Abstract][Full Text] [Related]
3. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
4. Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1.
Kanamori A; Matsubara D; Saitoh Y; Fukui Y; Gotoh N; Kaneko S; Seiki M; Murakami Y; Inoue JI; Sakamoto T
Oncogene; 2020 Sep; 39(39):6218-6230. PubMed ID: 32826949
[TBL] [Abstract][Full Text] [Related]
5. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Byerly JH; Port ER; Irie HY
Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
[TBL] [Abstract][Full Text] [Related]
6. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
[TBL] [Abstract][Full Text] [Related]
8. Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy.
Jiang T; Zhu J; Jiang S; Chen Z; Xu P; Gong R; Zhong C; Cheng Y; Sun X; Yi W; Yang J; Zhou W; Cheng Y
Adv Sci (Weinh); 2023 Jun; 10(17):e2207257. PubMed ID: 37096846
[TBL] [Abstract][Full Text] [Related]
9. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
10. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
11. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
[TBL] [Abstract][Full Text] [Related]
12. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR.
Wang X; Chen T; Li C; Li W; Zhou X; Li Y; Luo D; Zhang N; Chen B; Wang L; Zhao W; Fu S; Yang Q
J Hematol Oncol; 2022 Aug; 15(1):122. PubMed ID: 36038948
[TBL] [Abstract][Full Text] [Related]
13. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
[TBL] [Abstract][Full Text] [Related]
14. NECAB3 Promotes Activation of Hypoxia-inducible factor-1 during Normoxia and Enhances Tumourigenicity of Cancer Cells.
Nakaoka HJ; Hara T; Yoshino S; Kanamori A; Matsui Y; Shimamura T; Sato H; Murakami Y; Seiki M; Sakamoto T
Sci Rep; 2016 Mar; 6():22784. PubMed ID: 26948053
[TBL] [Abstract][Full Text] [Related]
15. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
[TBL] [Abstract][Full Text] [Related]
16. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
[TBL] [Abstract][Full Text] [Related]
17. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
19. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.
Koh SB; Ross K; Isakoff SJ; Melkonjan N; He L; Matissek KJ; Schultz A; Mayer EL; Traina TA; Carey LA; Rugo HS; Liu MC; Stearns V; Langenbucher A; Saladi SV; Ramaswamy S; Lawrence MS; Ellisen LW
Clin Cancer Res; 2021 Sep; 27(17):4883-4897. PubMed ID: 34168046
[TBL] [Abstract][Full Text] [Related]
20. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
Liao L; Zhang YL; Deng L; Chen C; Ma XY; Andriani L; Yang SY; Hu SY; Zhang FL; Shao ZM; Li DQ
Cancer Res; 2023 Feb; 83(3):471-484. PubMed ID: 36484700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
